Abstract Submission

DEADLINE EXTENDED TO 18 January 2017 23:59 CET (UTC +1)!

To submit your abstract, please go to http://www.abstractserver.com/cistm15/absmgm/. For questions regarding your abstract submission, please contact the CISTM15 abstract team at CISTMSPC@istm.org. Please note: you will need to establish a unique account on the abstract server website. Your ISTM username and account login will not work in that program. If you submitted an abstract for CISTM14, you can use the same account as before.

Download the PDF here


Call for Abstracts

CISTM15 invites you to submit an abstract for poster or oral presentations under the following categories:

  • AIR TRAVEL
  • DESTINATION
  • DISASTER/CONFLICTS/MILITARY
  • DURING TRAVEL
  • EDUCATION/TRAINING
  • ENVIRONMENT (altitude, diving, etc.)
  • IMPACT ON HOST COUNTRY
  • INFECTIOUS DISEASES (including microbial resistance)
  • MALARIA
  • MASS GATHERINGS
  • MIGRANTS (immigrants, refugees)
  • NON-INFECTIOUS DISEASE TRAVEL RISKS (pulmonary embolism, jet lag, trauma, security, etc.) 
  • ONE HEALTH AND ZOONOSES
  • POST-TRAVEL
  • PRETRAVEL PREP/ADVICE
  • SPECIAL TRAVELER (pregnancy, pediatrics, elderly, immunosuppressed, students, business travelers, military, long-stay travelers/ expatriates, etc.)
  • SPECIALTY TRAVEL (expeditions, wilderness, medical relief, etc.)
  • VACCINES
  • VECTORBORNE (excluding malaria)
 

Top of page

Summary of Abstract Submission Guidelines

Please follow the submission guidelines closely:

  • Abstracts can only be submitted online via the conference website
  • List authors – Given/first name(s) and the Family/last name(s).
  • Use short and concise title. Capitalize the first letter of each word except prepositions, articles and species names.
  • The abstract itself must contain no more than 350 words.
 
  • It is strongly recommended to structure the text as follows:
    • Background of the study
    • Objective(s)
    • Method(s)
    • Summary of results in sufficient detail to support the conclusions.
    • Conclusion(s) reached (it is not satisfactory to state “The results will be discussed”).
  • Simple table and graphs may be included.
  • All specific or unusual abbreviations must be defined in parentheses after the first instance of the word for which they stand.
  • Specific names of microorganisms should either be in italics or underlined (i.e. Plasmodium falciparum or Plasmodium falciparum)
  • For therapeutic agents, only generic names should be used.
  • Select one of the main topics (and subcategory, if one is listed) from the category list in the submission system.
  • Incorrectly prepared abstracts will not be considered for presentation.
  • Only abstracts written in English will be accepted.
  • Duplicate abstracts are not allowed. Submitted abstracts that contain similar or duplicate information from the same authors and institution will be disqualified.
  • Abstracts of articles that are published or accepted for publication at the time of submission will not be accepted. 
  • Ethics approval must be obtained and mentioned for study designs involving human subjects (not required for studies such as systematic reviews etc.)
  • Always check the final abstract with the system’s preview function before submission, and edit or replace as necessary. It is the author’s responsibility to submit a correct abstract. Any errors in spelling, grammar or scientific fact will be reproduced as typed by the author.
  • Do not forget to type the name, address, phone and fax number, as well as e-mail address, of the presenting author where indicated.

 
Please note: Abstract authors will be asked to disclose any financial interests or commercial products that are related to the research presented. Ethics approval must be obtained and mentioned for study designs involving human subjects (not required for studies such as systematic reviews etc.)
 
Posters selected for the CISTM15 will need to be displayed beginning Monday, 15 May 2017 until the end of the poster session on Wednesday, 17 May. Special poster tours are scheduled for Tuesday, 16 May, and authors will need to be present for these sessions. Authors on abstracts selected for poster presentation should plan to attend the Conference from 15-17 May 2017.


Top of page

Important Dates

18 January 2017:  Abstract Submission Deadline
 
March 2017: Notice of acceptance status to authors
Please note that only the corresponding author will receive mail concerning the abstract and is responsible for informing all co-authors of the status of the abstract. Authors whose abstracts have been accepted will receive instructions for the presentation of their abstract.
 
 3 April 2017: Deadline for author Congress registration
Please note that authors must have registered to attend the CISTM15 by this date to present their abstract.


Top of page

Abstract Preparation and Format

You must create an account in the system to submit abstracts. An example of a correctly formatted abstract follows:

Topic: Immunizations - Yellow Fever

Delayed Antibody Response to Yellow Fever Vaccination in Elderly Coincides with Prolonged Viraemia
Authors1
1Affiliations
Background: The live attenuated 17D yellow fever vaccine is regarded as one of the safest vaccines. However, it can cause vaccine-associated disease that resembles wild type yellow fever (yellow fever vaccine associated viscerotropic disease, YEL-AVD). The risk of YEL-AVD increases with a history of thymectomy, male gender and higher age. For vaccinees of 60-69 years, this risk is estimated to be 1.1:100.000 doses and for vaccinees of >70 years it is 3.2:100.000, a 4.4 and 13.4 fold higher risk than for young adults.

Objective: We investigated the humoral immune response against YF-17D in elderly subjects, to investigate the mechanism of YEL-AVD.

Method: Young volunteers (age range 18-28 yrs, N=30) and elderly travelers (age range 60-81 yrs, N=28) were vaccinated with YF-17D from the same vaccine batch. Neutralizing antibody titers and plasma YF-17D RNA copy numbers were measured at day 3, 5, 10, 14 and 28 after vaccination. Following vaccination, adverse events were documented in a diary during 3 weeks.

Results: Ten days after vaccination seroprotection (80% virus neutralization in plaque assay by minimally diluted serum) was attained by 77% (23/30) of the young participants and by 50% (14/28) of the elderly (p = 0.03, x2 test). At day 10, the younger participants had a GMT of 0.18 IU/ml, ten-fold higher than the GMT in the elderly (0.017 IU/ml) (p = 0.004). At day 14 the GMT also differed (respectively 4.8 IU/ml and 2.7 IU/ml, p = 0.035). Seroprotection was attained by all participants (young and elderly) by day 14. Viraemia was more common in the elderly (86%, 24/28) than in the younger participants (60%, 14/30) (p=0.03). In addition viral levels were higher in the elderly than in younger participants and correlated with the occurrence of systemic adverse events.

Conclusion: We found that elderly subjects (age >60 yrs) had a delayed antibody response and higher viraemia following yellow fever vaccine after primo vaccination. We hypothesize that this allows attenuated virus to cause higher viraemia levels that may result in severe disease.

348 Words